source
- Eli Lilly to buy psychedelics biotech AtaiBeckley for $2.8 billionEli Lilly announced it will acquire AtaiBeckley, a biotech focused on psychedelic therapies for mental health, for an upfront cash payment of $2.8 billion. The purchase adds a new dimension to Lil…
- Merck secures US approval for the first oral PCSK9 cholesterol-lowering pill, edging out AstraZenecaMerck has received the United States regulatory clearance for an oral PCSK9 inhibitor, marking the first time a pill of this class has been approved for cholesterol management. The approval comes…